{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:42:18Z","timestamp":1791380538309,"version":"4.3.3"},"reference-count":21,"publisher":"MedWorks Media","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"\n Background<\/jats:title>\n Tourette syndrome (TS) is a neurodevelopmental disorder characterized by motor and vocal tics that can cause significant functional impairment. Deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, has been evaluated in randomized controlled trials (RCTs) for tic reduction; however, individual studies have reported mixed results across clinical outcomes. We conducted a systematic review and meta-analysis to assess the efficacy and safety of deutetrabenazine compared with placebo in patients with Tourette syndrome.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A comprehensive literature search of PubMed, Embase, Scopus, and ClinicalTrials.gov was performed to identify randomized controlled trials evaluating deutetrabenazine versus placebo in Tourette syndrome up to October 2025. Primary outcomes included changes in Yale Global Tic Severity Scale (YGTSS), Tourette Syndrome\u2013Clinical Global Impression (TS-CGI), Tourette Syndrome\u2013Patient Global Impression of Improvement (TS-PGII), and Children and Adolescents\u2013Gilles de la Tourette Syndrome Quality of Life (C&A-GTS-QOL). Secondary outcomes included depressive symptoms assessed by the Children\u2019s Depression Inventory-2 (Parent Version) and the incidence of adverse events. Random-effects meta-analyses using restricted maximum likelihood estimation were conducted, with risk of bias assessed using the Cochrane Risk of Bias 2.0 tool.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Three RCTs comprising 297 participants were included. Deutetrabenazine was associated with a statistically significant reduction in tic severity compared with placebo as measured by YGTSS (MD = \u22120.61; 95% CI: \u22121.15 to \u22120.07; p = 0.039), with no observed heterogeneity (I2 = 0%). No statistically significant differences were observed for TS-CGI, TS-PGII, C&A-GTS-QOL, or depressive symptoms. The risk of adverse events did not differ significantly between deutetrabenazine and placebo (RR = 1.18; 95% CI: 0.62 to 2.26; p = 0.39).<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Deutetrabenazine demonstrates a modest but statistically significant reduction in tic severity in patients with Tourette syndrome, with a favorable safety profile. However, improvements in tic severity did not translate into significant benefits in global clinical impression, quality of life, or depressive symptoms. These findings support the role of deutetrabenazine as a potential adjunctive treatment for selected patients, while underscoring the importance of multimodal management strategies and further long-term studies.<\/jats:p>\n <\/jats:sec>","DOI":"10.64719\/pb.18519","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:56:35Z","timestamp":1780995395000},"page":"66-81","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Deutetrabenazine in Tourette Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.64719","volume":"56","author":[{"given":"Muneeb Ahmad","family":"Muneer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Haris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meerub","family":"Sajjad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnoor","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoya","family":"Ehtsham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubaba","family":"Amaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaseen Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqib Mumtaz","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Bukhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Kazim Raza","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Tehseen","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"ref1","unstructured":"Gilles de la Tourette syndrome | Nature Reviews Disease Primers [Internet] 2025 [cited 2025 Nov 28]. Available from: https:\/\/www.nature.com\/articles\/nrdp201697."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Knight T, Steeves T, Day L, Lowerison M, Jette N, Pringsheim T. Prevalence of tic disorders: a systematic review and meta-analysis. Pediatr Neurol. 2012;47(2):77\u201390.","DOI":"10.1016\/j.pediatrneurol.2012.05.002"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Groth C, Skov L, Lange T, Debes NM. Predictors of the clinical course of Tourette syndrome: a longitudinal study. J Child Neurol. 2019;34(14):913\u2013921.","DOI":"10.1177\/0883073819867245"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Piacentini J, Woods DW, Scahill L et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA [Internet] 2010;303(19):1929\u20131937. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20483969\/","DOI":"10.1001\/jama.2010.607"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Pringsheim T, Okun MS, M\u00fcller-Vahl K et al. Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):896\u2013906.","DOI":"10.1212\/WNL.0000000000007466"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Jankovic J, Jimenez-Shahed J, Budman C et al. Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (N Y). 2016;6:422.","DOI":"10.5334\/tohm.287"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Jankovic J, Coffey B, Claassen DO et al. Safety and efficacy of long-term deutetrabenazine use in children and adolescents with tics associated with Tourette syndrome: an open-label extension study. Mov Disord Clin Pract. 2023;10(9):1388\u20131398.","DOI":"10.1002\/mdc3.13849"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Coffey B, Jankovic J, Claassen DO et al. Efficacy and safety of fixed-dose deutetrabenazine in children and adolescents for tics associated with Tourette syndrome: a randomized clinical trial. JAMA Netw Open. 2021;4(10):e2129397.","DOI":"10.1001\/jamanetworkopen.2021.29397"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Whittington C, Pennant M, Kendall T et al. Practitioner review: treatments for Tourette syndrome in children and young people - a systematic review. J Child Psychol Psychiatry. 2016;57(9):988\u20131004.","DOI":"10.1111\/jcpp.12556"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Makhoul K, Jankovic J. Real-world experience with VMAT2 inhibitors in Tourette syndrome. Journal of neurology [Internet] 2023;270(9):4518\u20134522. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37301806\/","DOI":"10.1007\/s00415-023-11769-0"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Koch G, Motta C, Bonn\u00ec S et al. Effect of rotigotine vs placebo on cognitive functions among patients with mild to moderate alzheimer disease: a randomized clinical trial. JAMA Netw Open [Internet] 2020;3(7):e2010372. Available from: https:\/\/www.embase.com\/search\/results?subaction=viewrecord&id=L632357834&from=export.","DOI":"10.1001\/jamanetworkopen.2020.10372"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"ref13","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions | Cochrane [Internet] 2025 [cited 2025 Nov 28]. Available from: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook."},{"key":"ref14","unstructured":"Teva Branded Pharmaceutical Products R&D, Inc. A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents [Internet] clinicaltrials.gov; 2021 Nov [cited 2025 Nov 28]. Report No.: NCT03452943. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03452943."},{"key":"ref15","unstructured":"Teva Branded Pharmaceutical Products R&D, Inc. A Well-Controlled, Fixed-Dose Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tics Associated With Tourette Syndrome [Internet] clinicaltrials.gov; 2021 Nov [cited 2025 Nov 28]. Report No.: NCT03571256. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03571256."},{"key":"ref16","unstructured":"Teva Branded Pharmaceutical Products R&D, Inc. An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents [Internet] clinicaltrials.gov; 2021 Nov [cited 2025 Nov 28]. Report No.: NCT03567291. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03567291."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Jankovic J, Coffey B, Claassen DO et al. Safety and efficacy of flexible-dose deutetrabenazine in children and adolescents with Tourette syndrome: a randomized clinical trial. JAMA Netw Open. 2021;4(10):e2128204.","DOI":"10.1001\/jamanetworkopen.2021.28204"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Alharthi MS. A narrative review of Phase III and IV clinical trials for the pharmacological treatment of Tourette\u2019s syndrome in children, adults, and older adults. Medicine (Baltimore). 2025;104(23):e42760.","DOI":"10.1097\/MD.0000000000042760"},{"key":"ref19","unstructured":"Nikkhah A. A brief review on the role of vesicular monoamine transporter2 inhibitors in hyperkinetic movement disorders. Iran J Child Neurol. 2021;15(3):29\u201333."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Quezada J, Coffman KA. Current approaches and new developments in the pharmacological management of Tourette syndrome. CNS Drugs. 2018;32(1):33\u201345.","DOI":"10.1007\/s40263-017-0486-0"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Behling E, Farhat LC, Landeros-Weisenberger A, Bloch MH. Meta-analysis: efficacy and tolerability of vesicular monoamine transporter type 2 inhibitors in the treatment of tic disorders. Mov Disord. 2022;37(4):684\u2013693.","DOI":"10.1002\/mds.28957"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:37:08Z","timestamp":1791315428000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/efficacy-and-safety-of-deutetrabenazine-in-tourette-syndrome-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.18519","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]}}}